Literature DB >> 30206716

The critical role of comorbidities and polypharmacy in lower risk myelodysplastic patients: is there any difference between countries?

Priscila da Silva Mendonça1, Ronald Pinheiro Feitosa2, Silvia Maria Meira Magalhães2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30206716     DOI： 10.1007/s12032-018-1205-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  3 in total

1.  Risk and timing of cardiovascular death among patients with myelodysplastic syndromes.

Authors:  Andrew M Brunner; Traci M Blonquist; Gabriela S Hobbs; Philip C Amrein; Donna S Neuberg; David P Steensma; Gregory A Abel; Amir T Fathi
Journal:  Blood Adv       Date:  2017-10-18

2.  Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

Authors:  Matteo G Della Porta; Luca Malcovati; Corinna Strupp; Ilaria Ambaglio; Andrea Kuendgen; Esther Zipperer; Erica Travaglino; Rosangela Invernizzi; Cristiana Pascutto; Mario Lazzarino; Ulrich Germing; Mario Cazzola
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

3.  The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.

Authors:  Roberto Castelli; Riccardo Schiavon; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2018-02-08       Impact factor: 3.064
  3 in total
  1 in total

1.  Exploring polypharmacy burden among elderly patients with chronic diseases in Chinese community: a cross-sectional study.

Authors:  Yongli Wang; Xiaodan Li; Dongmei Jia; Beilei Lin; Bo Fu; Bei Qi; Zhenxiang Zhang
Journal:  BMC Geriatr       Date:  2021-05-13       Impact factor: 3.921
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.